BACKGROUND: To explore the relationship of the serum squamous cell carcinoma antigen (SCC-Ag) with the pathologic characteristics, occurrence, and prognosis of cervical squamous carcinoma. METHODS: The enzyme-linked immunosorbent assay (ELISA) method was used to determine the serum SCC-Ag levels for the patients, which included 424 pretreatment patients and 500 cases after treatment. RESULTS: (a) Pretreatment SCC-Ag levels of patients were related to clinical stages, lymphatic metastasis, and myometrial invasion, (b) within a median follow-up of 54 months, 180 recurrences (36%) and 102 disease-associated deaths (20.4%) were recorded, 161 recurrent patients showed elevated SCC-Ag levels (161/180, 89.4%), and 60 of them (37.3%) had a significant increase in SCC-Ag serum levels before clinical manifestation of relapse. The lead time ranged between 1 and 5 months (median: 2.3 months). The total survival rates were 23.4% and 17.8% for 3-year and 5-year period, respectively, and (c) clinical stages, the site of recurrence, and SCC-Ag levels after treatment were closely related with recurrent patients' survival time (P < 0.01~<0.005). Multivariate analysis indicated that the clinical stages and SCC-Ag levels of recurrent patients were independent prognostic factors (P < 0.05˜0.01). CONCLUSION: Serum SCC-Ag level was an important predictor for the cervical squamous carcinoma recurrence and prognosis.
BACKGROUND: To explore the relationship of the serum squamous cell carcinoma antigen (SCC-Ag) with the pathologic characteristics, occurrence, and prognosis of cervical squamous carcinoma. METHODS: The enzyme-linked immunosorbent assay (ELISA) method was used to determine the serum SCC-Ag levels for the patients, which included 424 pretreatment patients and 500 cases after treatment. RESULTS: (a) Pretreatment SCC-Ag levels of patients were related to clinical stages, lymphatic metastasis, and myometrial invasion, (b) within a median follow-up of 54 months, 180 recurrences (36%) and 102 disease-associated deaths (20.4%) were recorded, 161 recurrent patients showed elevated SCC-Ag levels (161/180, 89.4%), and 60 of them (37.3%) had a significant increase in SCC-Ag serum levels before clinical manifestation of relapse. The lead time ranged between 1 and 5 months (median: 2.3 months). The total survival rates were 23.4% and 17.8% for 3-year and 5-year period, respectively, and (c) clinical stages, the site of recurrence, and SCC-Ag levels after treatment were closely related with recurrent patients' survival time (P < 0.01~<0.005). Multivariate analysis indicated that the clinical stages and SCC-Ag levels of recurrent patients were independent prognostic factors (P < 0.05˜0.01). CONCLUSION: Serum SCC-Ag level was an important predictor for the cervical squamous carcinoma recurrence and prognosis.
Authors: F Legge; V Chiantera; G Macchia; A Fagotti; F Fanfani; A Ercoli; V Gallotta; A G Morganti; V Valentini; G Scambia; G Ferrandina Journal: Gynecol Oncol Date: 2015-05-01 Impact factor: 5.482
Authors: Nathalie Reesink-Peters; Jacobus van der Velden; Klaske A Ten Hoor; H Marike Boezen; Elisabeth G E de Vries; Marten S Schilthuis; Marian J E Mourits; Hans W Nijman; Jan G Aalders; Harry Hollema; Elisabeth Pras; Jitze M Duk; Ate G J van der Zee Journal: J Clin Oncol Date: 2005-03-01 Impact factor: 44.544
Authors: Elvira M Davelaar; Jonas van de Lande; Silvia von Mensdorff-Pouilly; Marinus A Blankenstein; René H M Verheijen; Peter Kenemans Journal: Tumour Biol Date: 2008-05-23
Authors: J M Duk; K H Groenier; H W de Bruijn; H Hollema; K A ten Hoor; A G van der Zee; J G Aalders Journal: J Clin Oncol Date: 1996-01 Impact factor: 44.544
Authors: Franca Forni; Gabriella Ferrandina; Francesco Deodato; Gabriella Macchia; Alessio G Morganti; Daniela Smaniotto; Stefano Luzi; Giuseppe D'Agostino; Vincenzo Valentini; Numa Cellini; Bruno Giardina; Giovanni Scambia Journal: Int J Radiat Oncol Biol Phys Date: 2007-08-06 Impact factor: 7.038